BLUE - Bluebird bio reports new data for sickle cell gene therapy program at ASH2021

bluebird bio (NASDAQ:BLUE) announces updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease (SCD). Shares up 9.3% premarket at $9.79. In addition to continued complete resolution of severe vaso-occlusive events (VOEs), patients in Group C achieved near normal levels of key hemolysis markers and experienced sustained improvements in patient-reported quality of life following treatment. The data were presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition; selected data of the HGB-206 study were also published in The New England Journal of Medicine (NEJM). Updated HGB-206 Group C Efficacy & Safety Data Following engraftment, median total hemoglobin increased from 8.5 g/dL at baseline to ?11 g/dL from six through up to 36 months post-infusion in all patients. Sickle hemoglobin (HbS) in all patients was <60% of total hemoglobin, and gene therapy-derived anti-sickling hemoglobin, HbAT87Q, contributed at least 40% of total hemoglobin.

For further details see:

Bluebird bio reports new data for sickle cell gene therapy program at ASH2021